{ "schemaVersion": "deck-intelligence.v1", "id": "019de075-da5f-7126-b0c8-5ad6b3fad507", "slug": "2367b4018d9bb2d1e01ea441f685753d", "title": "Neumora Therapeutics | IPO Presentation Deck | 32 slides", "subtitle": "Neumora Therapeutics · 2023-09", "author": "Neumora Therapeutics", "date": "2023-09-01 00:00:00", "pageCount": 32, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7794254, "document": { "id": "019de075-da5f-7126-b0c8-5ad6b3fad507", "slug": "2367b4018d9bb2d1e01ea441f685753d", "title": "Neumora Therapeutics | IPO Presentation Deck | 32 slides", "rawTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides", "authorId": "neumora-therapeutics", "authorName": "Neumora Therapeutics", "authorDisplay": "Neumora Therapeutics", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2023-09__neumora-therapeutics__ipo__2367b401.pdf", "sourceUrl": "https://www.slidebook.io/company/neumora-therapeutics/presentation/2367b4018d9bb2d1e01ea441f685753d/", "sourceDate": "2023-09-15 00:00:00", "presentationDate": "2023-09-01 00:00:00", "ingestedAt": "2026-04-30 22:15:13.349019+00", "status": "ready", "pageCount": 32, "orientation": "landscape", "aspectRatio": 1.7794254, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "drug-manufacturers-specialty-generic", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-09__neumora-therapeutics__ipo__2367b401", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 32, "pagesIndexed": 32, "pagesWithImages": 32, "pagesWithMetadata": 32, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 168, "chartCount": 9, "metricSlides": 0, "toolMatches": 10, "documentToolMatches": 0, "frameworkMatches": 11, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "evidence": "The deck's structure, starting with an executive summary, team bio, and roadmap, and progressing to specific pipeline updates and market analysis, aligns with the Sparkline narrative shape.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:37:49.814057+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 9, "name": "Complication", "beatId": "ae418749-a82f-4297-ba0f-ee67621e0c10", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "evidence": "Slides highlighting the limitations of current treatments and the unmet needs in brain disease treatment.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 10, "name": "Evidence", "beatId": "d8d5c84b-60b8-4c4d-81e2-30e06c864ec8", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "Slides showcasing Navacaprant's efficacy and safety data.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 8, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 8, "name": "Solution", "beatId": "6e6023e0-0615-40b5-b8c5-2313f80d541d", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": null, "evidence": "Slides presenting Navacaprant as a potential first novel mechanism approved in MDD in decades.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 15, "name": "Market Sizing", "beatId": "71a39db9-74d4-4c7b-8ac8-ff73acc17ac3", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": null, "evidence": "A slide estimating the large MDD patient population and potential upside for Navacaprant.", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 10, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "2bd7ba03-4d81-4e19-bd9c-4d10d02b1402", "evidence": "The complication slides highlighting current treatment limitations.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in brain disease treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.023379+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 12, "from": 10, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "79f06519-3b69-4341-b391-de3522d321e9", "evidence": "The traction slides showcasing Navacaprant's efficacy and safety data.", "position": 1, "objective": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.060119+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5494dcc1-1288-4e63-af4f-d84aed8a38cb", "evidence": "chart/bar-horizontal: Pipeline progress chart showing programs across Preclinical, Phase 1, Phase 2, and Phase 3 stages.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:24.648497+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ad26aa30-49a2-4b76-b273-5124b763eac3", "evidence": "list/bullet: Broad pipeline addressing some of the most prevalent brain health disorders; Targeting novel mechanisms; Scaling pipeline; Multiple clinical trial initiations; Strong IP.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:24.609452+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "31ce5f5d-5317-4b36-b7ea-752eafa9b532", "evidence": "table/data: Product Candidate MDD Severity Criteria table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:24.761508+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5cc02940-04eb-4bc2-be25-cfed03c38b65", "evidence": "table/data: Clinical efficacy data table with columns for Week 4 and Week 8 differences and p-values across various symptom improvement metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:24.87556+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "98ee2ac9-4bed-4c11-8077-c364bc15f65c", "evidence": "table/data: TEAEs Incidence (>2% in either treatment group). Placebo n=102, Navacaprant n=102. Preferred Terms: Headache 5(4.9) 5(4.9), COVID-19 3(2.9) 4(3.9), Nausea 1(1.0) 5(4.9), Diarrhea 3(2.9) 2(2.0), Upper respirat", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:24.950416+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "402f46f0-bd79-4d5e-81f3-5201546b3df3", "evidence": "table/data: KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary table of inclusion criteria and endpoints", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:25.024945+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6c44a312-eeb4-40fb-9108-e4c8041c6a14", "evidence": "Comparison table of Emraclidine, KarXT, and NMRA-266 across 6 pharmacological metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:06.136321+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Segmentation", "slug": "audience-segmentation", "status": "active", "bestFor": null, "canonId": "019dd956-8079-7046-8e6b-ecdf1bf15590", "version": 1, "bodyDocId": null, "description": "Grouping audience by attitude toward your message: Champions, Neutrals, Skeptics", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "4f7a2287-151b-463e-a7c1-d68f1c53d8cb", "evidence": "Incorporating machine learning mediated ALS patient clustering from the Answer ALS (AALS) data set with NMRA-CK1δ transcriptomic drug signature enriches for subpopulations distinct patient population", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:06.278205+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0aec0133-6ed1-4f0b-9bd4-54c778a3d3aa", "evidence": "Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and commercial potential creating rich set of catalysts", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:06.454638+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ea50ba4a-e257-440b-9c2a-6dfd4f1dbc11", "evidence": "table/data: Demographics and baseline characteristics table comparing Placebo QD (n=83) and Navacaprant 80 mg QD (n=88) across age, sex, ethnicity, race, BMI, HAMD-17, and SHAPS scores.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:14.945757+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "886d35c6-d744-4018-b41c-0ab77e748967", "evidence": "The pipeline table uses horizontal bars to represent the stage of development for each program over time/phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "gantt-chart" }, { "matchId": "02dd62d1-d40f-448e-8d55-1fab9d471cec", "evidence": "The diagram illustrates the causal link between stress, KOR activation, neurotransmitter dysregulation, and clinical symptoms.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "causal-chain" }, { "matchId": "b86f5a0b-cb60-48b5-aa60-11d2f12c2b2d", "evidence": "Contrasts 'Inherited from BlackThorn' with 'Neumora Amendments to Optimize Trial'", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "before-after-framing" }, { "matchId": "bc79270f-2b31-439e-a92b-fbb1dcd0264a", "evidence": "Standardized representation of RCT phases, endpoints, and inclusion criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "clinical-trial-design" }, { "matchId": "3d54f36a-05a8-42de-a076-c7098964658a", "evidence": "Table comparing product attributes against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_frame" }, { "matchId": "1793b49e-bffc-4823-b5ac-6c29c9f74b1f", "evidence": "The patient funnel diagram segments the total addressable market into treated and line-of-therapy segments.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "730b6b98-41af-4b5c-b7ee-74457733f388", "evidence": "The diagram maps clinical outcomes to specific next-step decisions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "decision-tree" }, { "matchId": "cc8a6ce4-e3c4-4157-8ca3-154d1c5a593d", "evidence": "The diagram illustrates a signal-seeking stage with decision gates based on effect size.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "adaptive-clinical-trial-design" }, { "matchId": "94f4664d-8891-4648-8cf6-db97e63f7fb0", "evidence": "The slide describes segmenting a patient population into distinct groups based on drug signatures.", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "e140b3d9-bbf2-4338-b8bf-e439d1726f47", "evidence": "Linear flow from challenge to solution to outcome", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "process" }, { "matchId": "bc499dcd-d322-4f5d-9df5-5f63597b0099", "evidence": "Chronological progression of clinical milestones from 2023 to 2025.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/H6ggnSEqBkSetbYME-uUyuVBUJOvjw8Up8lSBxF2H6U/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzY3YjQwMThkOWJiMmQxZTAxZWE0NDFmNjg1NzUzZC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 73, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.085+00", "seconds": 4.721, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/1", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-1", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.176, "x": 0.074, "y": 0.264 }, "kind": "image", "text": "Neumora", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5c759c2-780c-4b8b-b8d4-b869981604c4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.12, "x": 0.074, "y": 0.714 }, "kind": "paragraph", "text": "September 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c95b23d2-69d1-42ee-a19d-2f6d2897e5a0", "parentComponentId": null }, { "bbox": { "h": 0.11, "w": 0.38, "x": 0.074, "y": 0.438 }, "kind": "title", "text": "Pioneering a New Era of Innovation for Brain Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "95567475-bf17-4fa9-a4b8-593ad1d841ed", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/YBTpA45G5bBFtM15vhbNGOOfhqwwlN3L8kwoDVn2dOQ/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzY3YjQwMThkOWJiMmQxZTAxZWE0NDFmNjg1NzUzZC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/UX4qdp_0jvQ5h21xqLFeG6Tp0GkPeyPQnJnYs0ax-n4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzY3YjQwMThkOWJiMmQxZTAxZWE0NDFmNjg1NzUzZC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/lAhVcXAAmZXELWWl4K7EPpdUjYtYj2CO5MaKsbAvDU4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzY3YjQwMThkOWJiMmQxZTAxZWE0NDFmNjg1NzUzZC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 6, "textChars": 4351, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.487+00", "seconds": 4.117, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/2", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-2", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.64 }, "kind": "disclaimer", "text": "Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications and other data obtained from third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "57376f57-5295-4d4e-9fb8-555799a57501", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.23 }, "kind": "disclaimer", "text": "This presentation contains certain \"forward-looking statements\" within the meaning of applicable securities laws. These forward-looking statement include, but are not limited to, those regarding the Neumora's strategy, intellectual property matters, Neumora's clinical development plans and timelines, regulatory matters, and market size and opportunity. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. Such statements reflect the current views of Neumora with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about Neumora, including, without limitation, risks inherent in developing therapeutic products, future results from Neumora's ongoing and planned clinical trials, Neumora's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, the legal and regulatory framework for the industry and future expenditures. Although we have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. You should not rely on forward-looking statements as a prediction of future events.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68010908-429b-4b3e-b375-37b9ba395a44", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.54 }, "kind": "disclaimer", "text": "The assumptions used in the preparation of this presentation, although considered reasonable by us at the time of preparation, may prove to be incorrect. You are cautioned that the information is based on assumptions as to many factors and that actual results may vary from the results projected and such variations may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained herein. We do not undertake to update any forward-looking statements, except in accordance with applicable securities laws.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c2a9255-d7a2-4114-8916-aa601fa49f89", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.12 }, "kind": "disclaimer", "text": "This presentation has been prepared by Neumora on a confidential basis and is made for informational purposes only. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents, without the prior consent of Neumora is prohibited. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92433716-374c-4e36-aa5b-de5fc0b0c4fe", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.72 }, "kind": "disclaimer", "text": "This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with Neumora Therapeutics, Inc (\"Neumora,\" \"we\" or \"us\") and determining whether such investors might have an interest in a securities offering contemplated by Neumora. No such offering is being made at this time. Any such offering of securities will only be made by means of a registration statement (including a prospectus) filed with the U.S. Securities and Exchange Commission (the \"SEC\"), after such registration statement becomes effective. No such registration statement has been filed, or become effective, as of the date of this communication. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97bde35d-f0c3-4345-9f48-6ad67d6d5a74", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Important Disclosures", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.487+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35f48823-a9af-48e2-a741-de09b517b856", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "summarize", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 2, "textChars": 1033, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:36.536+00", "seconds": 7.166, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/3", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-3", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.96, "x": 0.02, "y": 0.18 }, "kind": "table", "text": "Issuer (Exchange / Ticker): Neumora Therapeutics, Inc. (Nasdaq / NMRA)\nBase offering size: 14,710,000 shares (100% primary)\nOption to purchase additional shares: 2,206,500 shares (15% of base deal, 100% primary)\nPrice range: $16.00 - $18.00 per share\nUse of proceeds: Neumora Therapeutics anticipates to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, as follows: approximately $395 million to fund the clinical and preclinical development of our current programs; approximately $30 million to fund research and development activities for additional programs; and the remainder for working capital and other general corporate purposes.\nBookrunners: J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets, William Blair\nStabilization agent: J.P. Morgan\nExpected pricing date: As early as Thursday, September 14th, 2023\nLock-up: 180 days for the Company, directors, officers, affiliates and substantially all security holders", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:36.536+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd5ecea3-a57e-46a8-b914-9fd52dadeec8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Offering summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:36.536+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d69b08c-0c24-41f9-9a3f-99459d4a9f71", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 237, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:31.946+00", "seconds": 2.552, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/4", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-4", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.2, "x": 0.08, "y": 0.07 }, "kind": "image", "text": "Neumora", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.946+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13d9b50a-1ae0-4808-892b-c2f87ccf60c2", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.55, "x": 0.45, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.946+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1152e511-c662-452c-a704-5f25f2489eb9", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.09, "y": 0.335 }, "kind": "paragraph", "text": "We are focused on redefining neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.946+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b62cb4c6-0613-41c4-97ac-2d3c4651240a", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.09, "y": 0.285 }, "kind": "title", "text": "Our Mission", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.946+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4985bc87-d1ce-4b62-ba9f-97c35384dfdb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 5, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 7, "textChars": 646, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.517+00", "seconds": 6.088, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/5", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-5", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.15, "x": 0.12, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70fd2a68-566f-4afb-ac31-2c5ebca45753", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.42, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d45db768-7197-4b54-b50e-8581ab61c6e8", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.72, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0a6d0a9-0c47-46ac-8f92-8ef33991d7d1", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.35, "y": 0.45 }, "kind": "list", "text": "Leading Pipeline: Focus on therapeutic candidates with novel MOAs; Improve the efficiency of development and potentially increase the odds of clinical success; Advancing seven novel programs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b6dd9bf-f436-4819-aead-b9d1a251968f", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "Built at Scale: Raised over $600M to date from leading investors; Experienced company builders and leading neuroscience drug developers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30645e12-5e87-473a-8df9-48ffeea41d76", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.65, "y": 0.45 }, "kind": "list", "text": "Near-Term Catalysts: Navacaprant entering Phase 3 pivotal studies in MDD in 3Q23 with readout expected in 2H24; NMRA-511 study in Alzheimer's disease agitation expected to initiate in 1H24; NMRA-266 IND submission expected in 4Q23; Advancing preclinical programs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54765e70-63f9-4de8-a87a-4138fdeb811d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Focused on Building the Leading Global Brain Health Company", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48df294c-e95f-41da-82a8-99d3e58628a3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "3bd59596-460d-4a33-994d-5327f8bc4717", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 6, "type": "setup", "title": "The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 15, "componentCount": 3, "textChars": 126, "nDataPoints": 0, "notes": "The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:31.678+00", "seconds": 2.055, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/6", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-6", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.55, "x": 0.02, "y": 0.2 }, "kind": "image", "text": "Leadership team headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.678+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c24da75c-1519-4ee2-91ac-6015f2a19943", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.38, "x": 0.6, "y": 0.2 }, "kind": "image", "text": "Blue Chip Investors logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.678+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32f7be15-8559-470d-bc72-7898a4ebf520", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Led by Experienced Company Builders and Leading Neuroscience Drug Developers", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:31.678+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce176ec0-9617-4b0c-a888-c07959bdf1ef", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 569, "nDataPoints": 10, "notes": "The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.022+00", "seconds": 3.334, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/7", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-7", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.65, "x": 0.32, "y": 0.21 }, "kind": "chart", "text": "Pipeline progress chart showing programs across Preclinical, Phase 1, Phase 2, and Phase 3 stages.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0164cabe-cb5b-45d7-8ed5-ebee8f1845ac", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.03, "y": 0.22 }, "kind": "list", "text": "Broad pipeline addressing some of the most prevalent brain health disorders; Targeting novel mechanisms; Scaling pipeline; Multiple clinical trial initiations; Strong IP.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "544bac2d-1677-43a9-831e-60b8eb27d91f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.03, "y": 0.72 }, "kind": "metric", "text": "60M Total addressable U.S. population; 7 Development programs", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3de69713-4ade-4190-8cf4-8e43ebeda740", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.94 }, "kind": "source-note", "text": "1) National Institute of Mental Health, 2021. 2) National Alliance of Mental Illness, 2017. 3) Figure includes total addressable U.S. population across all neurosychiatric and neurodegenerative indications", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f0c6bbb-d6ee-4b01-9f54-454ff03ff65a", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Advancing Our Neuroscience Pipeline", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd236290-4778-4a1f-b6b2-2fc150258f8d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5494dcc1-1288-4e63-af4f-d84aed8a38cb", "evidence": "chart/bar-horizontal: Pipeline progress chart showing programs across Preclinical, Phase 1, Phase 2, and Phase 3 stages.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:24.648497+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ad26aa30-49a2-4b76-b273-5124b763eac3", "evidence": "list/bullet: Broad pipeline addressing some of the most prevalent brain health disorders; Targeting novel mechanisms; Scaling pipeline; Multiple clinical trial initiations; Strong IP.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:24.609452+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "886d35c6-d744-4018-b41c-0ab77e748967", "evidence": "The pipeline table uses horizontal bars to represent the stage of development for each program over time/phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.022+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "resolution", "title": "Includes a detailed biological mechanism diagram showing the interaction of KOR, dynorphin, and neurotransmitters.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 7, "textChars": 699, "nDataPoints": 2, "notes": "Includes a detailed biological mechanism diagram showing the interaction of KOR, dynorphin, and neurotransmitters.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.015+00", "seconds": 3.317, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/8", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-8", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.1, "x": 0.43, "y": 0.18 }, "kind": "callout", "text": "Strong Biological Rationale: KOR/dynorphin in are important regulators of stress-induced alterations in reward processing, mood states and cognition", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e153b27-4bd8-4483-8433-aa4aaf4c6aad", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.43, "x": 0.55, "y": 0.18 }, "kind": "image", "text": "Mechanism of action diagram showing KOR antagonism by NMRA-140 and its effect on neurotransmitters.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a38abec-55c6-4806-b64e-5e7cccb14ff7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.02, "y": 0.78 }, "kind": "list", "text": "Drug Profile: Oral, once-daily, 80 mg dose. Strong IP Protection: Exclusivity through 2041.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83e2e255-9b46-46d8-bad8-0cabd90ba1ef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.02, "y": 0.18 }, "kind": "list", "text": "Pharmacologic Profile: Selective KOR antagonist, >300-fold selectivity, 90% receptor occupancy.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db3a0d6c-9dca-4017-b6c3-89993d5a807c", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.02, "y": 0.36 }, "kind": "paragraph", "text": "Pathophysiology: The KOR/dynorphin system is a well-characterized pathway known to modulate depression, anhedonia, and anxiety.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "693ac02d-f104-46a5-ab32-6e6653cc63d2", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.02, "y": 0.09 }, "kind": "title", "text": "Potential to be first novel mechanism approved in MDD in decades", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49d15fde-0ca9-4c71-bdd2-5909505a2a25", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.88, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Navacaprant: KOR Antagonism has Potential for Broad Neuropsychiatric Impact", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51449b9e-5fc1-44b3-8f68-7ff9eb9b7183", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "02dd62d1-d40f-448e-8d55-1fab9d471cec", "evidence": "The diagram illustrates the causal link between stress, KOR activation, neurotransmitter dysregulation, and clinical symptoms.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.015+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "causal-chain" } ], "arcBeats": [ { "to": 8, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "6e6023e0-0615-40b5-b8c5-2313f80d541d", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": null, "evidence": "Slides presenting Navacaprant as a potential first novel mechanism approved in MDD in decades.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.", "function": "establish_context", "rawType": "context", "block": null, "metadata": { "slideType": "context", "slideTypeCanon": { "name": "Context (pitchdeck)", "slug": "context", "status": "active", "canonId": "019de52d-1094-779e-9590-e4603e6a191c", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 8, "textChars": 576, "nDataPoints": 12, "notes": "The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.115+00", "seconds": 3.152, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/9", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-9", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.35, "x": 0.02, "y": 0.35 }, "kind": "chart", "text": "Inherited from BlackThorn trial timeline", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "716c9bd5-d0be-4cf3-89d0-35074cafbe42", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.42, "y": 0.7 }, "kind": "list", "text": "Neumora Amendments to Optimize Trial details", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fe77d8d-1602-473d-9955-c04849d994de", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.02, "y": 0.7 }, "kind": "list", "text": "Initial Study Inclusion (pre-Neumora) details", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "431948e5-97c2-41b3-b9e6-ea1b4e7a0c42", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.2, "x": 0.78, "y": 0.21 }, "kind": "paragraph", "text": "Study Endpoints and Final Efficacy Population", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0be516fc-4a56-4839-bedf-865de7833683", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.02, "y": 0.95 }, "kind": "source-note", "text": "1) Patients with a baseline HAMD-17 total score that received at least one dose of study drug and had at least one post-baseline HAMD-17 assessment 2) Baseline HAMD-17 score ≥22", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5aa97d7-73ba-477d-8981-94ce3babb569", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.42, "y": 0.345 }, "kind": "table", "text": "Product Candidate MDD Severity Criteria table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7fcd452-9d82-4249-a0db-e224f2b5e11b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Navacaprant: Phase 2a Trial Design Amended by Neumora after Acquisition of BlackThorn", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65fd29a3-78da-470d-850c-2d2cd094d828", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.02, "y": 0.09 }, "kind": "title", "text": "Amendments included expanding enrollment criteria to allow patients with moderate-to-severe MDD", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc999372-c832-42f5-a298-4d3bc54446b3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "31ce5f5d-5317-4b36-b7ea-752eafa9b532", "evidence": "table/data: Product Candidate MDD Severity Criteria table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:24.761508+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b86f5a0b-cb60-48b5-aa60-11d2f12c2b2d", "evidence": "Contrasts 'Inherited from BlackThorn' with 'Neumora Amendments to Optimize Trial'", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:31:33.115+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 9, "name": "Complication", "beatId": "ae418749-a82f-4297-ba0f-ee67621e0c10", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "evidence": "Slides highlighting the limitations of current treatments and the unmet needs in brain disease treatment.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 10, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "2bd7ba03-4d81-4e19-bd9c-4d10d02b1402", "evidence": "The complication slides highlighting current treatment limitations.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in brain disease treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.023379+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "evidence", "title": "Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 332, "nDataPoints": 12, "notes": "Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:32.806+00", "seconds": 2.451, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/10", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-10", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.45, "x": 0.05, "y": 0.2 }, "kind": "chart", "text": "HAMD-17 clinical trial results", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:32.806+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32120189-e646-45ce-baf3-a23b17f4cb65", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.45, "x": 0.55, "y": 0.2 }, "kind": "chart", "text": "SHAPS clinical trial results", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:32.806+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "485883c0-f5c9-4de4-90dd-c10df3851111", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.4, "y": 0.85 }, "kind": "legend", "text": "Placebo vs Navacaprant", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:32.806+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9d3713c-e41e-4ae9-ae1f-a8407a8832d5", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.05, "y": 0.95 }, "kind": "paragraph", "text": "Note: Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:32.806+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8b290d1-975b-432e-8715-861514216838", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Navacaprant: Established Proof-of-Concept for Treatment of Depression and Anhedonia in Patients with Moderate-to-Severe MDD", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:32.806+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2fa479a-99e9-44d5-9a95-a772771bc8a0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 9, "name": "Complication", "beatId": "ae418749-a82f-4297-ba0f-ee67621e0c10", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "evidence": "Slides highlighting the limitations of current treatments and the unmet needs in brain disease treatment.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 10, "name": "Evidence", "beatId": "d8d5c84b-60b8-4c4d-81e2-30e06c864ec8", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "Slides showcasing Navacaprant's efficacy and safety data.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 10, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "2bd7ba03-4d81-4e19-bd9c-4d10d02b1402", "evidence": "The complication slides highlighting current treatment limitations.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in brain disease treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.023379+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 12, "from": 10, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "79f06519-3b69-4341-b391-de3522d321e9", "evidence": "The traction slides showcasing Navacaprant's efficacy and safety data.", "position": 1, "objective": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.060119+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "The table displays statistical significance (p-values) for multiple clinical endpoints.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 3, "textChars": 346, "nDataPoints": 28, "notes": "The table displays statistical significance (p-values) for multiple clinical endpoints.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:36.92+00", "seconds": 6.46, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/11", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-11", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Note: Prespecified statistical sensitivity analysis for moderate-to-severe patients (HAMD-17 ≥ 22)", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:36.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aebca7fd-f8f4-46f2-b43f-4e187e7f9d03", "parentComponentId": null }, { "bbox": { "h": 0.68, "w": 0.62, "x": 0.19, "y": 0.225 }, "kind": "table", "text": "Clinical efficacy data table with columns for Week 4 and Week 8 differences and p-values across various symptom improvement metrics.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:36.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ba34edb-b589-4326-a3f6-671843afb724", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.75, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Navacaprant: Demonstrated Efficacy Across Broad Range of Treatment Outcome Measures in Moderate-to-Severe Population", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:36.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "190ec816-b764-47db-a52e-421b271c5ba9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5cc02940-04eb-4bc2-be25-cfed03c38b65", "evidence": "table/data: Clinical efficacy data table with columns for Week 4 and Week 8 differences and p-values across various symptom improvement metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:24.87556+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 10, "name": "Evidence", "beatId": "d8d5c84b-60b8-4c4d-81e2-30e06c864ec8", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "Slides showcasing Navacaprant's efficacy and safety data.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 10, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "79f06519-3b69-4341-b391-de3522d321e9", "evidence": "The traction slides showcasing Navacaprant's efficacy and safety data.", "position": 1, "objective": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.060119+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "evidence", "title": "TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 3, "textChars": 1040, "nDataPoints": 16, "notes": "TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.44+00", "seconds": 2.656, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/12", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-12", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.48, "x": 0.02, "y": 0.24 }, "kind": "list", "text": "Navacaprant was well tolerated and demonstrated lower TEAE incidence rate compared to placebo: Overall discontinuation rates were higher on placebo compared to navacaprant (29% navacaprant and 37% placebo); Incidence rates of TEAEs were 35% (navacaprant) and 44% (placebo); Discontinuation rates related to TEAEs were higher on placebo compared to navacaprant (1% navacaprant and 12% placebo). The most common (>2%) TEAEs in the navacaprant group were mild to moderate in severity. Navacaprant was not associated with common side effects of current antidepressant therapies – such as weight gain or sexual dysfunction. No evidence of suicidal behavior was identified as assessed the Columbia Suicide Severity Rating Scale", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.44+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "881bdfa3-6a89-4f16-8fb4-9fae5aa5749e", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.42, "x": 0.54, "y": 0.28 }, "kind": "table", "text": "TEAEs Incidence (>2% in either treatment group). Placebo n=102, Navacaprant n=102. Preferred Terms: Headache 5(4.9) 5(4.9), COVID-19 3(2.9) 4(3.9), Nausea 1(1.0) 5(4.9), Diarrhea 3(2.9) 2(2.0), Upper respiratory tract infection 1(1.0) 3(2.9)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.44+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48b4a007-dd32-4ec6-9416-a81d62c0bd88", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.96, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Navacaprant: Well Tolerated with Lower TEAE Incidence Rate Compared to Placebo", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.44+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "715745a1-7dd3-42d8-adde-1a4baf875ab8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "98ee2ac9-4bed-4c11-8077-c364bc15f65c", "evidence": "table/data: TEAEs Incidence (>2% in either treatment group). Placebo n=102, Navacaprant n=102. Preferred Terms: Headache 5(4.9) 5(4.9), COVID-19 3(2.9) 4(3.9), Nausea 1(1.0) 5(4.9), Diarrhea 3(2.9) 2(2.0), Upper respirat", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:24.950416+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 10, "name": "Evidence", "beatId": "d8d5c84b-60b8-4c4d-81e2-30e06c864ec8", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "Slides showcasing Navacaprant's efficacy and safety data.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 10, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "79f06519-3b69-4341-b391-de3522d321e9", "evidence": "The traction slides showcasing Navacaprant's efficacy and safety data.", "position": 1, "objective": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:50.060119+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 968, "nDataPoints": 0, "notes": "Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.583+00", "seconds": 3.747, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/13", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-13", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.6, "x": 0.36, "y": 0.18 }, "kind": "diagram", "text": "Pivotal Efficacy Studies timeline showing screening, randomization, treatment, and OLE enrollment", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c39c002-6479-491f-a7fe-b906c310de28", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.36, "y": 0.91 }, "kind": "disclaimer", "text": "Safety Assessments include Change in Sexual Functioning Questionnaire (CSFQ-14). CGI-I = Clinical Global Impression-Improvement scale; CGI-S = Clinical Global Impression-Severity scale; EQ-5D 5L = EuroQol-5D 5L; HAM-A = Hamilton Anxiety Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; MDD = major depressive disorder; PHQ-9 = Patient Health Questionnaire-9; QD = once daily; SDS = Sheehan Disability Scale; SHAPS = Snaith-Hamilton Pleasure Scale; wk = week; WPAI-GH = Work Productivity and Activity Impairment Questionnaire – General Health.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36ee4959-52dd-4aac-8a9d-114c5fd84e24", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.29, "x": 0.04, "y": 0.24 }, "kind": "list", "text": "KOASTAL-1: Planned 3Q23 Initiation; KOASTAL-2: Planned 1Q24 Initiation; KOASTAL-3: Planned 4Q23 Initiation; KOASTAL-LT: Planned 2H23 Initiation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "695085b3-630c-4eda-b2a3-192b98310f09", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.6, "x": 0.36, "y": 0.6 }, "kind": "table", "text": "KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary table of inclusion criteria and endpoints", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68252ac5-3534-4989-b804-594b628f3d04", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.96, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Pivotal Studies Designed to Evaluate Potential Benefits of Navacaprant Monotherapy in MDD", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc174ef1-3b15-4f4a-872c-42955143e1a3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "402f46f0-bd79-4d5e-81f3-5201546b3df3", "evidence": "table/data: KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary table of inclusion criteria and endpoints", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:25.024945+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "bc79270f-2b31-439e-a92b-fbb1dcd0264a", "evidence": "Standardized representation of RCT phases, endpoints, and inclusion criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.583+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "clinical-trial-design" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "setup", "title": "The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 644, "nDataPoints": 0, "notes": "The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.952+00", "seconds": 3.028, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/14", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-14", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.78, "x": 0.17, "y": 0.83 }, "kind": "callout", "text": "Most providers prefer navacaprant compared to approved agents due to navacaprant's novel mechanism, superior dosing and side effect profile. Some providers would still use recently launched novel agents in patients who are unwilling to wait two or more weeks for onset.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db1ea260-6f7c-4832-998e-5ef461858aec", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.95 }, "kind": "disclaimer", "text": "Independent market research, interviews, and analysis conducted by L.E.K. Consulting, March 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a64d33b1-76cc-4344-901b-98baf10ec2a1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.05, "y": 0.83 }, "kind": "legend", "text": "Degree of preference: High (Green), Medium (Light Green), Low (Yellow)", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1b30be6-1ea2-471b-81b1-b1e7bd1b6d00", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.185 }, "kind": "table", "text": "Comparison table of Navacaprant vs Approved Agents across Novel Mechanism, Dosing, Side Effect Profile, and Efficacy.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9dd08f2-bcaf-4aca-84c9-a2aac9190628", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Navacaprant: Differentiated Profile Relative to Approved Agents Drives Physician Preference", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c79d2fd-d9b0-4150-89f5-385b79eb71f3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "3d54f36a-05a8-42de-a076-c7098964658a", "evidence": "Table comparing product attributes against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:33.952+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "resolution", "title": "Includes qualitative expert testimonials regarding pricing and market access.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 76, "componentCount": 6, "textChars": 783, "nDataPoints": 16, "notes": "Includes qualitative expert testimonials regarding pricing and market access.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.728+00", "seconds": 3.761, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/15", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-15", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.55, "x": 0.02, "y": 0.18 }, "kind": "diagram", "text": "MDD patient funnel from 21M diagnosed to 3-5% net penetration", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd318bfa-de26-475b-a8dd-2f231c3bdf2a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.96, "x": 0.02, "y": 0.85 }, "kind": "list", "text": "Upside drivers: Safer agent drives treatment seeking, Patients fast fail 1st line, Safer agent drives compliance, Inflation adjusted pricing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c882773b-23dd-4186-ab2f-cf309cbae33b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.38, "x": 0.6, "y": 0.65 }, "kind": "quote", "text": "...is a combo of two products that exist; I would expect a pretty steep discount, for example 50-60% is going to be what it takes ... [navacaprant] is a lower discount since it is a unique MOA ... Executive, Magellan", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22c5b13e-ad70-4963-b108-d2bc701bb004", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.38, "x": 0.6, "y": 0.78 }, "kind": "quote", "text": "... 15-25% or up to 30% are reasonable discounts [for navacaprant] a few years after launch, given it's a new MoA as an antidepressant, that's a big benefit ... Pharmacy Director, Anthem BCBS OH", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d16b7c2-a30b-4038-aa21-ba80513c8270", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.38, "x": 0.6, "y": 0.18 }, "kind": "table", "text": "Neuropsychology Pricing Catalogues", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1ab2f17-6c00-4995-8d97-d422772e78bf", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.96, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Navacaprant: MDD Market in U.S. Provides Potential Large Blockbuster Opportunity for Differentiated Product with Novel Mechanism of Action", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cbae2174-865f-4dc9-a490-84c5c104dda3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "1793b49e-bffc-4823-b5ac-6c29c9f74b1f", "evidence": "The patient funnel diagram segments the total addressable market into treated and line-of-therapy segments.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:34.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 15, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 15, "name": "Market Sizing", "beatId": "71a39db9-74d4-4c7b-8ac8-ff73acc17ac3", "matchId": "f0c3d1ab-3f4f-420b-b5ab-3129dd5f9833", "beatType": null, "evidence": "A slide estimating the large MDD patient population and potential upside for Navacaprant.", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "resolution", "title": "The diagram illustrates a decision-tree process based on clinical trial outcomes.", "function": "plan_implementation", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 762, "nDataPoints": 0, "notes": "The diagram illustrates a decision-tree process based on clinical trial outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.617+00", "seconds": 3.598, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/16", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-16", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.5, "x": 0.45, "y": 0.25 }, "kind": "diagram", "text": "Signal-seeking study in patients with BPD enables decision-making on advancing navacaprant to proceed to pivotal program in BPD", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f23e7691-050d-4133-af5b-74147951e549", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.4, "x": 0.04, "y": 0.35 }, "kind": "list", "text": "Evidence from the navacaprant Phase 2 study and the NIMH-sponsored FASTMAS demonstrate the utility of KOR pharmacology for depression and anhedonia symptoms. Anhedonia is a highly prevalent and clinically relevant symptom in BPD. Navacaprant studies have demonstrated meaningful improvements in anhedonia symptoms in patients with moderate-to-severe MDD. The primary endpoint for evaluating efficacy in bipolar depression is MADRS. Currently approved therapies have significant limitations.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5920cc34-7ceb-41d3-8a85-72661a40ceff", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.04, "y": 0.27 }, "kind": "paragraph", "text": "Strong Rationale for Efficacy in Bipolar Depression (BPD):", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "032ed84e-00fc-4b61-9745-5b396c61e273", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Potential for Broad Applicability of Navacaprant Beyond MDD Includes Bipolar Depression", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a36866c1-c4c6-495e-af15-e938d88ebd0c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "730b6b98-41af-4b5c-b7ee-74457733f388", "evidence": "The diagram maps clinical outcomes to specific next-step decisions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.617+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "decision-tree" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "resolution", "title": "Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 5, "textChars": 802, "nDataPoints": 2, "notes": "Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.971+00", "seconds": 2.902, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/17", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-17", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.18, "x": 0.37, "y": 0.18 }, "kind": "callout", "text": "Strong Biologic Activity Demonstrated: NMRA-511 reduced measures of anxiety in an NHP preclinical model, with a corresponding EEG signature in Phase 1", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.971+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3ff21de-a44b-446c-a786-694437085710", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.4, "x": 0.56, "y": 0.18 }, "kind": "image", "text": "Mechanism of action diagram showing V1aR expression in brain regions and intracellular signaling pathway (Gq/11, PLC, DAG, PKC, Ca2+).", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.971+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0620de2-0cbd-429b-a29d-d57e14a898e6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.05, "y": 0.18 }, "kind": "list", "text": "Pharmacology: Antagonist of vasopressin 1a receptor (V1aR), with high selectivity over V1b, V2 and oxytocin receptors. Vasopressin plays a role in the regulation of aggression, affiliation, stress and anxiety response.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.971+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9467332f-990e-40f2-8ffb-cfc12b6754f6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.35, "x": 0.05, "y": 0.45 }, "kind": "paragraph", "text": "Indication: Agitation in Alzheimer’s disease. Status: Conducting Phase 1 Multiple Ascending Dose (MAD) study in human healthy volunteers. Drug Profile: Oral, once-daily. Strong IP Protection: Expect exclusivity through 2042+.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.971+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf697ccb-211b-4744-8c13-500e3b136211", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "NMRA-511: V1aR Antagonist Broad Potential Across Neuropsychiatric Disorders", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.971+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0281c82-d534-4215-a390-076d6c5e779f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "evidence", "title": "The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 76, "componentCount": 6, "textChars": 897, "nDataPoints": 8, "notes": "The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.822+00", "seconds": 3.553, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/18", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-18", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.55, "x": 0.42, "y": 0.18 }, "kind": "callout", "text": "Interim assessment using effect size in adaptive signal-seeking study provides opportunity to make an informed decision on advancing NMRA-511 program most efficiently", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25ebe95f-6c04-4bc1-b77d-2f079d3f793c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.36, "x": 0.03, "y": 0.52 }, "kind": "chart", "text": "Marmoset and Human EEG data showing change from baseline for theta and alpha waves.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e688e188-defa-4352-af2e-00fcc817227f", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.55, "x": 0.42, "y": 0.35 }, "kind": "diagram", "text": "Stage 1: Signal Seeking adaptive study design flow.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd4bf560-f7de-402c-9c52-78a9fd1cec74", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.36, "x": 0.03, "y": 0.18 }, "kind": "paragraph", "text": "In a human threat test study completed in marmosets, NMRA-511 demonstrated activity in brain circuits that regulate mood and anxiety. An additional EEG study demonstrated that the pharmacodynamic effects of NMRA-511 translated to humans.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1c6ce48-9c37-4288-a0fa-8d11f3dbbb3a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.03, "y": 0.94 }, "kind": "source-note", "text": "1) Wallace TL. et al, NMRA-511, a novel vasopressin 1a (V1a) receptor antagonist reduces threat behaviors in marmosets and alters EEG power spectra similarly in marmosets and humans. Presented at the American College of Neuropsychopharmacology 2022 Annual Congress.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "addf0ce9-7bc5-48c8-b6ab-6fbda6e0e0db", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "NMRA-511 Demonstrates Relevant Pharmacodynamics with the Potential to Address Anxiety Disorders", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6267022-f395-4302-a270-0b5a4e524110", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "cc8a6ce4-e3c4-4157-8ca3-154d1c5a593d", "evidence": "The diagram illustrates a signal-seeking stage with decision gates based on effect size.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:34.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "adaptive-clinical-trial-design" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "resolution", "title": "The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 88, "componentCount": 10, "textChars": 869, "nDataPoints": 1, "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.668+00", "seconds": 4.167, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/19", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-19", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.22, "w": 0.12, "x": 0.41, "y": 0.18 }, "kind": "callout", "text": "Emerging Clinical Activity: Muscarinic receptor-targeting compounds have demonstrated potential as an approach to treating schizophrenia", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f32f8f5c-994e-423a-a3ba-92acf94fe2f6", "parentComponentId": null }, { "bbox": { "h": 0.72, "w": 0.42, "x": 0.55, "y": 0.18 }, "kind": "image", "text": "Mechanism of action diagram showing M4R receptor interaction and neurotransmitter pathways", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79f0e339-eb04-4a62-bbdf-67574ad6491a", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.03, "y": 0.57 }, "kind": "paragraph", "text": "Status: Plan to submit IND to FDA in 4Q 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16c92825-8754-426b-81ed-a1cb1d3fced9", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.03, "y": 0.65 }, "kind": "paragraph", "text": "Drug Profile: Oral, once-daily", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c5865bf-fbdc-40a6-b5db-10f8d1b8d856", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.35, "x": 0.03, "y": 0.73 }, "kind": "paragraph", "text": "Strong IP Protection: Expect exclusivity through 2042+, based on composition of matter protection and estimated patent term extension", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70c02433-3574-4be2-bf04-a7e5a94267b7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.03, "y": 0.46 }, "kind": "paragraph", "text": "Epidemiology: Estimated 3 million patients in the U.S. with schizophrenia", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7991890d-faa7-45ef-9eff-901e318168be", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.03, "y": 0.18 }, "kind": "paragraph", "text": "Pharmacology: Designed as a highly selective positive allosteric modulator (PAM) for the M4 muscarinic receptor for antipsychotic-like efficacy with the potential for improved safety profile with an oral once-daily dosing profile", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a273f822-13d3-4dd1-8ce8-ad97bb0e5052", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.03, "y": 0.38 }, "kind": "paragraph", "text": "Indication: Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd429026-f956-482f-9aa8-26e9f924c465", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "1) Wander, C. Am J Manag Care. 2020;26:S62-S68.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "45fd860f-27e5-4f5c-9486-be6ed0b21e34", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "NMRA-266: Potentially Differentiated M4R PAM for Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.668+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3d5161a-0afc-4d7a-837d-b606da8101c3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 20, "type": "setup", "title": "The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 3, "textChars": 339, "nDataPoints": 18, "notes": "The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:33.931+00", "seconds": 2.218, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/20", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-20", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.88, "x": 0.06, "y": 0.92 }, "kind": "source-note", "text": "1. CERE Company data; 2. Heinrich, J.N., et al. Pharmacological comparisons of muscarininc ligands... 5. Neumora Company data. Note: Data on this slide is presented for illustrative purposes only...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c18865f0-577a-4c74-a888-6ddb81010fa9", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.72, "x": 0.24, "y": 0.25 }, "kind": "table", "text": "Comparison table of Emraclidine, KarXT, and NMRA-266 across 6 pharmacological metrics.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc4ed907-fc67-48c9-88ab-0259f2a2dbee", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "Profile of NMRA-266 is Comparable to Other M4R Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:33.931+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18e76eb1-0660-413e-b5fb-1f9ae5fcd1ba", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6c44a312-eeb4-40fb-9108-e4c8041c6a14", "evidence": "Comparison table of Emraclidine, KarXT, and NMRA-266 across 6 pharmacological metrics.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:06.136321+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 21, "type": "resolution", "title": "The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 9, "textChars": 894, "nDataPoints": 1, "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:39.426+00", "seconds": 7.663, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/21", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-21", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.12, "x": 0.41, "y": 0.17 }, "kind": "callout", "text": "Strong Biological Rationale: Glutamate is the major excitatory neurotransmitter in the brain and dysregulation is believed to be a key driver of schizophrenia", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41a77616-73ee-4f03-979f-649a995e9ec1", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.42, "x": 0.55, "y": 0.17 }, "kind": "image", "text": "Biological pathway diagram showing NMDA receptor, PAM interaction, and downstream effects on GABA and Dopamine pathways.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16e283b4-9a3a-4d1e-97c2-e1ddf38b0177", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.38, "x": 0.03, "y": 0.41 }, "kind": "list", "text": "Indication: Schizophrenia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "00f7b137-f87f-4e03-bba6-544876c79622", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.38, "x": 0.03, "y": 0.18 }, "kind": "list", "text": "Pharmacology: NMDA receptor hypofunction is a leading hypothesis for the cause of schizophrenia. NMDA positive allosteric modulators (PAMs) can selectively enhance physiological NMDAR function, decrease network hypersynchrony and improve symptoms.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c887919-1115-42af-a20f-a3cf1182b767", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.38, "x": 0.03, "y": 0.67 }, "kind": "list", "text": "Drug Profile: Oral, once-daily", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72004eef-3500-458b-aa29-152c075f00c3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.38, "x": 0.03, "y": 0.58 }, "kind": "list", "text": "Status: Undergoing IND-enabling activities", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9fd7ff7-54ff-4f7d-ab8f-55fe77835ad1", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.38, "x": 0.03, "y": 0.76 }, "kind": "list", "text": "Strong IP Protection: Expect exclusivity through 2044+, based on composition of matter protection plus potential for patent term extension", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9053349-bbcb-4413-9268-917232742f53", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.38, "x": 0.03, "y": 0.49 }, "kind": "list", "text": "Epidemiology: Estimated ~3 million patients in the U.S. with schizophrenia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f403fc37-e5cf-4811-bf7c-8a0576500291", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.8, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "NMRA-NMDA: Novel Approach for the Treatment of Schizophrenia", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:39.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f91affe-10f7-4734-99f9-190ca4a17ac4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "resolution", "title": "Includes a biological mechanism diagram showing the inhibition of TDP-43 phosphorylation by NMRA-CK1δ.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 8, "textChars": 779, "nDataPoints": 2, "notes": "Includes a biological mechanism diagram showing the inhibition of TDP-43 phosphorylation by NMRA-CK1δ.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.871+00", "seconds": 3.995, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/22", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-22", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.13, "x": 0.4, "y": 0.17 }, "kind": "callout", "text": "Strong Biological Rationale: CK1δ phosphorylates TDP-43, a key driver of TDP-43-driven pathology in ALS", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5fca555-5d6a-4613-98d2-249cc7c4e7c5", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.4, "x": 0.55, "y": 0.17 }, "kind": "image", "text": "Mechanism of action diagram showing CK1δ, TDP-43, and the inhibitory effect of NMRA-CK1δ.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c87117e-029c-44bd-9275-3f5cc612774c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.35, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Pharmacology: Focused on inhibiting CK1δ to reduce pathological TDP-43 and slow ALS progression; regulates tau biology.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "738732bc-9f32-4b23-872a-469637e81a88", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.35, "x": 0.04, "y": 0.75 }, "kind": "paragraph", "text": "Strong IP Protection: Expect exclusivity through 2043+, based on composition of matter protection plus potential for patent term extension.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0dad255d-1657-4568-b58a-d850ac96d4bb", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.35, "x": 0.04, "y": 0.58 }, "kind": "paragraph", "text": "Status: Discovery stage; identified compounds demonstrating CK1δ selectivity, nanomolar potency, and properties consistent with favorable CNS penetration.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb204cdf-0043-4f72-87a0-d8c1e7cf457c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.04, "y": 0.45 }, "kind": "paragraph", "text": "Epidemiology: ~5,000 people diagnosed in U.S. each year and ~16,000 patients in U.S. live with ALS at a given time.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d9a42bd8-46b1-42a4-a641-17b1ebc79036", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.04, "y": 0.95 }, "kind": "source-note", "text": "1) CDC.gov, 2018.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b74230d6-89f9-44bd-a141-9933f0668c51", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.5, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "NMRA-CK1δ for Amyotrophic Lateral Sclerosis", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2341bc22-227c-497c-af78-890a60bd1532", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "resolution", "title": "MVAE stands for Multimodal Variational Autoencoder.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 583, "nDataPoints": 2, "notes": "MVAE stands for Multimodal Variational Autoencoder.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.109+00", "seconds": 3.177, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/23", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-23", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.7, "x": 0.15, "y": 0.82 }, "kind": "callout", "text": "Characterizing more homogeneous patient populations has the potential to enable more targeted, biomarker driven clinical development plans", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3397b5a9-20f4-4f60-9709-29178c2301a8", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.05, "y": 0.45 }, "kind": "chart", "text": "Unsupervised MVAE Clustering", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c34fed2-0b38-458d-bac1-2d600d2e3729", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.55, "y": 0.45 }, "kind": "chart", "text": "Knowledge-Based MVAE Clustering", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc06c64b-ceb2-4a55-b40d-c1e21fc11404", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "paragraph", "text": "Incorporating machine learning mediated ALS patient clustering from the Answer ALS (AALS) data set with NMRA-CK1δ transcriptomic drug signature enriches for subpopulations distinct patient populations", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ca8cc73-6590-48fc-a7c7-49cdc6a29f79", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.05, "y": 0.94 }, "kind": "source-note", "text": "*MVAE: Multimodal Variational Autoencoder", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3b88a69-c2ad-421a-88e9-7809e6e29609", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Precision strategy for NMRA-CK1δ in Amyotrophic Lateral Sclerosis (ALS) incorporates drug specific properties to define potential best responders", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18ccc991-27a0-40ac-a0a8-505b638144f1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Segmentation", "slug": "audience-segmentation", "status": "active", "bestFor": null, "canonId": "019dd956-8079-7046-8e6b-ecdf1bf15590", "version": 1, "bodyDocId": null, "description": "Grouping audience by attitude toward your message: Champions, Neutrals, Skeptics", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "4f7a2287-151b-463e-a7c1-d68f1c53d8cb", "evidence": "Incorporating machine learning mediated ALS patient clustering from the Answer ALS (AALS) data set with NMRA-CK1δ transcriptomic drug signature enriches for subpopulations distinct patient population", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:06.278205+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "94f4664d-8891-4648-8cf6-db97e63f7fb0", "evidence": "The slide describes segmenting a patient population into distinct groups based on drug signatures.", "framework": null, "confidence": 0.6, "extraction": { "at": "2026-05-02 11:31:35.109+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "resolution", "title": "The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 625, "nDataPoints": 1, "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:38.037+00", "seconds": 6.09, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/24", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-24", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.12, "x": 0.41, "y": 0.18 }, "kind": "callout", "text": "Strong Biological Rationale: NLRP3 inflammasome is activated in microglia in response to disease linked proteins such as α-synuclein, leading to proinflammatory signaling in neurodegeneration diseases", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d40f7c2-c9c8-47d7-94ee-168200ce1f4d", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.42, "x": 0.54, "y": 0.18 }, "kind": "image", "text": "Mechanism of action diagram showing NMRA-NLRP3 inhibiting NLRP3 inflammasome formation and subsequent IL-1β release.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "313b7f4e-c697-449b-a04c-c4bb727d099b", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Pharmacology: Focused on inhibiting the NLRP3 inflammasome to modulate the immune response in neurodegeneration. Indication: Parkinson’s disease (PD). Epidemiology: ~1 million people in the U.S. have PD. Status: Discovery stage.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92ed427d-27fc-432a-a101-0d04d5dbd84a", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.17, "x": 0.11, "y": 0.96 }, "kind": "source-note", "text": "1) Yang et al. NPJ Parkinsons Dis. 2020; 6: 15.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c1b1b6e-b216-4809-bd8a-722aa44fb250", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "NMRA-NLRP3 for Parkinson’s Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d00cfc6-9fb9-4a3c-bbb0-4edbb7c469ca", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "resolution", "title": "Includes a detailed biological pathway diagram illustrating the mechanism of action.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 739, "nDataPoints": 1, "notes": "Includes a detailed biological pathway diagram illustrating the mechanism of action.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.714+00", "seconds": 3.749, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/25", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-25", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.12, "x": 0.41, "y": 0.18 }, "kind": "callout", "text": "Strong Biological Rationale: GCase deficiencies lead to lysosomal dysfunction and the accumulation of alpha-synuclein, a hallmark of PD", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ab7cbf7-ddc7-49fd-a20f-f159606512a6", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.42, "x": 0.55, "y": 0.18 }, "kind": "image", "text": "Mechanism of action diagram showing GCase, lysosome, and alpha-synuclein pathway", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51b52a19-a40a-4df7-a707-13cfcae15dd6", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.35, "x": 0.04, "y": 0.18 }, "kind": "paragraph", "text": "Pharmacology: Focused on elevating activity of the GCase enzyme, which is encoded by the GBA1 gene, and may help to degrade toxic a-synuclein aggregates. Indication: Parkinson’s disease (PD). Epidemiology: ~10% of PD patients have GBA mutations.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d8dcb2d-6329-448e-b4da-615e9ef98db2", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.04, "y": 0.95 }, "kind": "source-note", "text": "1) Avenali et al. Front. Aging Neurosci., 21 April 2020. 2) Gegg, ME, Schapira, AHV, The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J. 2018 Oct;285(19):3591-3603. doi: 10.1111/febs.14393. Epub 2018 Feb 19. PMID: 29385658.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54f453ca-574f-45be-ae20-469c0f73bf45", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "NMRA-GCase for Parkinson’s Disease", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "245d5c60-5771-4550-a595-42d8f76dc970", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "resolution", "title": "The slide uses a linear process flow (Challenge -> Toolbox -> Value) to explain the company's methodology.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 870, "nDataPoints": 0, "notes": "The slide uses a linear process flow (Challenge -> Toolbox -> Value) to explain the company's methodology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.871+00", "seconds": 3.637, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/26", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-26", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.6, "x": 0.2, "y": 0.85 }, "kind": "callout", "text": "Neumora applies precision medicine approaches to our programs on an as needed basis in a fit for purpose manner", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "877fafcf-3eda-4c94-a671-0eb3c35c4e69", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.96, "x": 0.02, "y": 0.2 }, "kind": "diagram", "text": "Challenge: Match Right Drug to the Right Patient -> Neumora’s Precision Toolbox -> Maximize Value: Improve Probability of Success & Expand Indications", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03864a77-4ad7-4bda-9e87-1badd1e1c712", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.03, "y": 0.365 }, "kind": "list", "text": "How do we gain further confidence in a selected target? How do we identify indications for a given target? How do we identify likely responders / treatment non-responders?", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27d729a6-ea07-4804-b4ae-515ea45e04f7", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.26, "x": 0.37, "y": 0.375 }, "kind": "list", "text": "Molecular, Translational, and Clinical Tools; Multimodal Methods; Longitudinal, Multi-modal patient datasets", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cae22db7-9fa3-4b2a-8eb9-ba577c7df209", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.26, "x": 0.71, "y": 0.365 }, "kind": "list", "text": "Gain confidence in target and/or indication; Characterize more homogeneous, targeted patient populations; Inform inclusion / exclusion criteria; Increase indication expansion opportunities; Identify placebo responders; Identify biomarkers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df867fe0-0ba2-4cfc-84c5-b41d1f38f550", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Neumora’s Precision Medicine Approach Can Be Leveraged to Maximize the Value of Our Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e8ff896-1df6-4baf-bf9c-134cb51fddee", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e140b3d9-bbf2-4338-b8bf-e439d1726f47", "evidence": "Linear flow from challenge to solution to outcome", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:35.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 1251, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.641+00", "seconds": 3.363, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/27", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-27", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.08, "x": 0.02, "y": 0.32 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6e02e33-2fb3-4b5a-bae9-1cd224e1a582", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.02, "y": 0.68 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d9ff975-5980-4629-80d2-4e2488ca2972", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.09, "y": 0.67 }, "kind": "list", "text": "Pipeline of Novel Mechanisms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1aab95db-1ac2-445b-b524-0760e6b2a39f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.09, "y": 0.3 }, "kind": "list", "text": "Company Built at Scale with Differentiated Approach", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "644079fc-0621-4508-ae3c-a536faacb91c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.7, "x": 0.25, "y": 0.61 }, "kind": "paragraph", "text": "Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and commercial potential creating rich set of catalysts\nLead program, navacaprant (KOR antagonist) demonstrated positive Phase 2 clinical data and is currently in Phase 3 trials with topline data expected in 2H 2024\nMid-stage clinical program, NMRA-511 (V1aR antagonist) expected to enter AD agitation studies in 1H 2024\nIND submission planned for NMRA-266 (M4 PAM) in the fourth quarter of 2023\nDeep preclinical pipeline with near-IND assets focused on Parkinson's, ALS and other indications", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "be4c0f73-d0d1-4b85-a395-622fd424dcc3", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.7, "x": 0.25, "y": 0.28 }, "kind": "paragraph", "text": "Raised >$600M to date from leading investors and collaborators, including Series B close in Oct. 2022\nLed by experienced company builders and leading neuroscience drug developers\nPrecision approach leveraging unique data sciences capability underlying development strategy\nStrong capital position to support growth with compelling use of proceeds story for proposed offering\nStrategy supported by long-dated composition of matter patents for each of our programs, into 2041+", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f31e762a-681d-4e94-aae2-3bb38c3d7cff", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Building a Company with the Scale and Scope to Address the Brain Disease Crisis for Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.641+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1727d59a-25d4-48f8-923f-adf3714e8606", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0aec0133-6ed1-4f0b-9bd4-54c778a3d3aa", "evidence": "Portfolio of seven clinical and preclinical programs targeting novel mechanisms of action, with large therapeutic and commercial potential creating rich set of catalysts", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:06.454638+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 542, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.117+00", "seconds": 2.836, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/28", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-28", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.92, "x": 0.04, "y": 0.35 }, "kind": "diagram", "text": "2023 to 2025 timeline with milestones", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3efc81a-2eb4-43e8-a8c8-4ef02c8d49cb", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.3, "x": 0.66, "y": 0.22 }, "kind": "paragraph", "text": "Innovative Approach: Maximizing the value of our programs to potentially increase the odds of clinical success and expand indications", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b66a6222-1b72-4775-aecf-18a4caa19d1f", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.3, "x": 0.04, "y": 0.22 }, "kind": "paragraph", "text": "Built at Scale: Raised >$600M to date from leading investors with a team of expert company builders and neuroscience drug developers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b7d9e7bc-986b-4277-9493-58596ee45dd2", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.3, "x": 0.35, "y": 0.22 }, "kind": "paragraph", "text": "Leading Pipeline: Advancing seven programs with NCE therapeutic candidates with novel MOAs in areas of significant unmet need", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ccbef3ab-120a-44f7-9f05-6b7b5739b28e", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.96, "x": 0.02, "y": 0.02 }, "kind": "title", "text": "Neumora is Poised to Become the Leader in Brain Health with Multiple Catalysts Expected Through 2025 to Drive Value", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "efbe538e-4c3c-4ab7-bdd6-ce86d7dd5d61", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "bc499dcd-d322-4f5d-9df5-5f63597b0099", "evidence": "Chronological progression of clinical milestones from 2023 to 2025.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:35.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "appendix", "function": "appendix", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "sparse", "densityScore": 17, "componentCount": 4, "textChars": 29, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:35.191+00", "seconds": 2.899, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/29", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-29", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.05, "x": 0.88, "y": 0.96 }, "kind": "disclaimer", "text": "Confidential", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fff8e5c4-d3c3-49c7-8f95-49d7d10bcf45", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.28, "x": 0.08, "y": 0.07 }, "kind": "image", "text": "Neumora", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0dddb7cc-59ff-438c-b104-b95ff5d075ac", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.02, "x": 0.96, "y": 0.96 }, "kind": "paragraph", "text": "29", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "889b37c6-abed-44f9-b2fc-fac0dcc03d37", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.08, "y": 0.78 }, "kind": "title", "text": "Appendix", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:35.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78954a5a-d366-4eef-804c-34d440a3ee91", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "setup", "title": "The slide uses a table to demonstrate IP defensibility and a green footer section to categorize the IP strategy.", "function": "other", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 909, "nDataPoints": 14, "notes": "The slide uses a table to demonstrate IP defensibility and a green footer section to categorize the IP strategy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:38.114+00", "seconds": 5.745, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/30", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-30", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.3, "x": 0.02, "y": 0.58 }, "kind": "disclaimer", "text": "*All dates are approximate / estimates / projections only. PTE = US patent term extension. +Estimates do not include PTE", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0392dfb7-30a2-457d-a5de-80ae92c7c8a1", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.68, "y": 0.68 }, "kind": "paragraph", "text": "Biomarkers: Approximate higher responding clusters. Method of treatment patent protection. Cover selecting patients with biomarker and treating with drug/class.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b52f8f6-6e65-4d09-b0db-15a409147c8b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.04, "y": 0.68 }, "kind": "paragraph", "text": "Portfolio of Drugs: All new chemical entities. Composition of matter patents for each program. Favorable expiration dates.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "829a466d-ee47-463e-b2a4-654e9f049403", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.36, "y": 0.68 }, "kind": "paragraph", "text": "Precision Platform: AI/ML approach to find higher responding patients. High-level, AI/ML process patent protection for Data Processing, Patient Stratification and Target / Drug Discovery + Translation. Trade secret protection of underlying details.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd70c000-b628-4422-92fa-cead3c5aa76b", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.96, "x": 0.02, "y": 0.13 }, "kind": "table", "text": "Target, Composition of Matter Patent Status, Base Patent Expiration / Patent Expiration with PTE*", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1188e049-b925-4df3-ad23-5296b048b2f6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.96, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Differentiated IP Position Includes Composition of Matter Protection with Favorable Expiration Dates Across Programs and Process Protection for Precision Platform", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.114+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aaf80115-c738-481b-aaf0-959272aa061d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "analysis", "title": "Clinical trial baseline characteristics table.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 3, "textChars": 515, "nDataPoints": 42, "notes": "Clinical trial baseline characteristics table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:34.821+00", "seconds": 2.425, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/31", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-31", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.85, "x": 0.04, "y": 0.94 }, "kind": "disclaimer", "text": "The Efficacy population includes all randomized subjects who received at least 1 dose of study drug, have a baseline HAMD-17 assessment total score, and have at least 1 valid post-baseline HAMD-17 assessment total score.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b1d1865-2afb-4513-bbc3-a6bae044aac6", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.92, "x": 0.04, "y": 0.165 }, "kind": "table", "text": "Demographics and baseline characteristics table comparing Placebo QD (n=83) and Navacaprant 80 mg QD (n=88) across age, sex, ethnicity, race, BMI, HAMD-17, and SHAPS scores.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ec44dd2-ffda-4b04-96ba-56711812e616", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.02, "y": 0.03 }, "kind": "title", "text": "Navacaprant Phase 2 Efficacy Population: Patient Demographics and Baseline Characteristics Similar Across Treatment Groups", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:34.821+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99e744f8-cb93-49a2-96f6-48ca70ef9cb9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ea50ba4a-e257-440b-9c2a-6dfd4f1dbc11", "evidence": "table/data: Demographics and baseline characteristics table comparing Placebo QD (n=83) and Navacaprant 80 mg QD (n=88) across age, sex, ethnicity, race, BMI, HAMD-17, and SHAPS scores.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:14.945757+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "evidence", "title": "The slide uses two line charts to visualize clinical trial data with p-values and delta LSM values.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 216, "nDataPoints": 10, "notes": "The slide uses two line charts to visualize clinical trial data with p-values and delta LSM values.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:38.217+00", "seconds": 5.146, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/32", "deck": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507", "deckAnchor": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-32", "deckJson": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.4, "x": 0.55, "y": 0.2 }, "kind": "chart", "text": "SHAPS Anhedonia scale", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.217+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71fed02f-eaa7-4f1e-91b6-623157a9f605", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.4, "x": 0.08, "y": 0.2 }, "kind": "chart", "text": "HAMD-17 Primary endpoint", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.217+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74a94846-e44f-47fe-8b8a-bc6d2107f0f1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.4, "y": 0.85 }, "kind": "legend", "text": "Placebo Navacaprant", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.217+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "660101de-f158-4f0e-b851-b0ebc33fc59c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Navacaprant Demonstrated Statistically Significant and Clinically Meaningful Improvements in Depression and Anhedonia Despite Inclusion of Mild Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:38.217+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d95cee8-fb6c-40d9-a28b-e4ab1599372f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 5, "label": "Setup", "description": "The cover, mission, executive summary, and team bio slides provide an introduction to the company and its goals." }, { "from": 9, "to": 10, "label": "Complication", "description": "Slides highlighting the limitations of current treatments and the unmet needs in brain disease treatment." }, { "from": 10, "to": 12, "label": "Evidence", "description": "Slides showcasing Navacaprant's efficacy and safety data." }, { "from": 8, "to": 8, "label": "Solution", "description": "Slides presenting Navacaprant as a potential first novel mechanism approved in MDD in decades." }, { "from": 15, "to": 15, "label": "Market Sizing", "description": "A slide estimating the large MDD patient population and potential upside for Navacaprant." } ], "loops": [ { "from": 9, "to": 10, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing the unmet needs in brain disease treatment?" }, { "from": 10, "to": 12, "label": "Jobs To Be Done", "description": "How can Navacaprant address the unmet needs in depression and anhedonia treatment?" } ] }